The COVID-19 pandemic has caused chaos all over the world, leading to considerable premature death, medical and also economic costs. The success from the vaccination program has given some light at the end of the tunnel and because the vaccine strategy spreads out, economies about the world are starting to open up. The ending of lockdowns will not be without having its risks and you will find increases in cases as different countries ease limitations. The vaccine program has lessened the risks for the seriousness of the infection as well as decreased the potential risk of being hospitalised and dying in those who are vaccinated. Infections continue to be taking place in the vaccinated, however the overwhelming majority and the much more serious cases happen to be in those people who are not immunized. The health system has got considerably better at dealing with patients with COVID-19 as the knowledge about the illness improves and a lot more treatment options are discovered. Several therapies currently have different degrees of data which support the approaches and there are already numerous false starts with what seems to be good treatments are not able to offer the benefits that were believed. A considerable amount of false information and pseudoscience in addition underpins the therapy statements for COVID-19. There is certainly a need for much more specified treatments and recommendations. The requirement for clinicians to have far more tools and treatments are quickly required to fight the COVID-19 crisis. A number of drugs are in clinical trials.
On the 1 October 2021, the pharmaceutical drug firm Merck put out a press release reporting the results with a medical trial using the antiviral drug, molnupiravir for people with COVID-19. The administration committee with the clinical trial discontinued the study ahead of time because the effects were considered so good. will be making an application for an emergency use permission from the Federal Drug Administration. In the clinical study, 775 patients that had minor to moderate COVID-19 infection were randomised to receiving molnupiravir or a control drug. In the group receiving the molnupiravir clearly there was a lower probability of hospitalization or death by around 50%. 7.3% of patients which were on the molnupiravir were either in the hospital or died by day 29 after starting the drug compared with 14.1% of placebo-treated people. At day 29, zero deaths were noted in individuals who got the molnupiravir, in comparison with eight fatalities in patients that were on the inactive drug. The outcome have already been extensively publicised in the press. While the results appear notable, a lot more investigation and clinical experience with the usage of the medication is important. The USA Department of Health and Human Services made a commitment to order 1.7 million of the molnupiravir for US$1.2 billion worth if it was licensed by the FDA. Merck wants to produce around ten million courses of the drug by the end of 2021, along with much more anticipated to be manufactured the following year. Merck in addition have committed to putting into action a tiered pricing strategy depending on the World Bank nation income factors to reflect a countries relative capacity to pay for their health response to the outbreak. They have also created licensing agreements with recognized generic manufacturers to accelerate the provision of the medicine in more than a hundred lower income countries.